BIOMAT Database Logo BIOMAT Database Logo

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2) 1990

C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006932 Hyperbilirubinemia A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdown product of HEME, is normally excreted in the BILE or further catabolized before excretion in the urine. Bilirubinemia,Bilirubinemias,Hyperbilirubinemias
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Recombinant Interleukin-2 (rIL-2), aldesleukin.
May 2002, Journal of biotechnology,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2).
January 1988, Acta dermato-venereologica,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Recombinant human interleukin 2 (rIL-2) enhancement of antibody production by human-human hybridomas.
September 1988, Cellular immunology,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
[The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
January 1995, Zhonghua zhong liu za zhi [Chinese journal of oncology],
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
[A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases].
January 1995, Vestnik khirurgii imeni I. I. Grekova,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
November 1990, Clinical and experimental immunology,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins.
January 1993, European journal of cancer (Oxford, England : 1990),
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Pharmacokinetic alteration in rats of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2.
April 1994, Biological & pharmaceutical bulletin,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2).
November 1986, Journal of clinical immunology,
C J Punt, and S C Henzen-Logmans, and R L Bolhuis, and G Stoter
Characterization of nucleosidediphosphate (NDP)-kinase-associated GTP binding proteins from human recombinant interleukin 2 (rIL-2)-treated mouse NK cells.
November 1985, Biochemistry international,
Copied contents to your clipboard!